Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 19/20 | 0.47 |
| ▸ | CBL | P22681 | 15/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25414599 | 1.00 | CBLB (0.47) | CBLBCBLGSK3BDYRK1ACBLC | |
| SCHEMBL25413018 | 0.80 | CBLB (0.48) | CBLBCBLCBLC | |
| SCHEMBL25413016 | 0.80 | CBLB (0.48) | CBLBCBLCBLC | |
| SCHEMBL31115401 | 0.80 | CBLB (0.63) | CBLBCBLCBLC | |
| SCHEMBL31578412 | 0.80 | CBLB (0.63) | CBLBCBLCBLC | |
| SCHEMBL25413553 | 0.79 | CBLB (0.44) | CBLBCBL | |
| SCHEMBL25413551 | 0.79 | CBLB (0.44) | CBLBCBL | |
| SCHEMBL31251387 | 0.78 | CBLB (0.46) | CBLBCBLCBLC | |
| SCHEMBL31275178 | 0.77 | CBLB (0.42) | CBLBCBLCBLC | |
| SCHEMBL30184959 | 0.76 | CBLB (0.52) | CBLBCBLCBLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | CBLB 1/4885CBL 2/4885GSK3B 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.